Summary
245.73 2.73(1.12%)07/01/2024
Alnylam Pharmaceuticals Inc (ALNY)
Alnylam Pharmaceuticals Inc (ALNY)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| 1.12 | 46.48 | 61.66 | 62.38 | 24.00 | 23.46 | 234.45 | 3,937.94 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 245.73 | |
| Open | 240.00 | |
| High | 245.99 | |
| Low | 239.85 | |
| Volume | 962,410 | |
| Change | 2.73 | |
| Change % | 1.12 | |
| Avg Volume (20 Days) | 1,817,637 | |
| Volume/Avg Volume (20 Days) Ratio | 0.53 | |
| 52 Week Range | 141.98 - 252.86 | |
| Price vs 52 Week High | -2.82% | |
| Price vs 52 Week Low | 73.07% | |
| Range | -2.59 | |
| Gap Up/Down | -3.74 | |
Fundamentals | ||
| Market Capitalization (Mln) | 30,738 | |
| EBIDTA | -122,297,000 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | -0.4900 | |
| WallStreet Target Price | 222.68 | |
| Book Value | -1.7340 | |
| Earnings Per Share | -2.6300 | |
| EPS Estimate Current Quarter | -1.1800 | |
| EPS Estimate Next Quarter | -1.0400 | |
| EPS Estimate Current Year | -3.6000 | |
| EPS Estimate Next Year | -1.8700 | |
| Diluted EPS (TTM) | -2.6300 | |
| Revenues | ||
| Profit Marging | -0.1658 | |
| Operating Marging (TTM) | -0.0879 | |
| Return on asset (TTM) | -0.0305 | |
| Return on equity (TTM) | -15.0066 | |
| Revenue TTM | 2,003,335,040 | |
| Revenue per share TTM | 15.9740 | |
| Quarterly Revenue Growth (YOY) | 0.5480 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | 868,601,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 142.9249 | |
| Revenue Enterprise Value | 9.6506 | |
| EBITDA Enterprise Value | -81.9647 | |
| Shares | ||
| Shares Outstanding | 126,492,000 | |
| Shares Float | 125,952,923 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.02 | |
| Insider (%) | 0.41 | |
| Institutions (%) | 93.83 | |
06/28 07:00 EST - forbes.com
What's Next For Alnylam Stock After A 60% Rise In A Week?
Alnylam Pharmaceuticals stock (NASDAQ: ALNY), a pharmaceutical company focused on RNA interference therapeutics for genetically defined diseases, has seen a significant rise of 60% in a week. This can be attributed to positive data from a late-stage clinical trial for its cardiovascular drug, Amvuttra.
What's Next For Alnylam Stock After A 60% Rise In A Week?
Alnylam Pharmaceuticals stock (NASDAQ: ALNY), a pharmaceutical company focused on RNA interference therapeutics for genetically defined diseases, has seen a significant rise of 60% in a week. This can be attributed to positive data from a late-stage clinical trial for its cardiovascular drug, Amvuttra.
06/25 10:00 EST - zacks.com
Alnylam (ALNY) Soars as Heart Disease Drug Study Meets Goals
Alnylam (ALNY) soars as its phase III study, seeking to expand Anvuttra's label to include the treatment of ATTR amyloidosis with cardiomyopathy, achieves primary and all secondary endpoints.
Alnylam (ALNY) Soars as Heart Disease Drug Study Meets Goals
Alnylam (ALNY) soars as its phase III study, seeking to expand Anvuttra's label to include the treatment of ATTR amyloidosis with cardiomyopathy, achieves primary and all secondary endpoints.
06/24 18:40 EST - youtube.com
Alnylam CEO on what is next for heart disease drug
CNBC's Angelica Peebles and Yvonne Greenstreet, Alnylam CEO, joins 'Fast Money' to talk the companies latest heart condition drug data and what the path to approval looks like.
Alnylam CEO on what is next for heart disease drug
CNBC's Angelica Peebles and Yvonne Greenstreet, Alnylam CEO, joins 'Fast Money' to talk the companies latest heart condition drug data and what the path to approval looks like.
06/24 11:37 EST - seekingalpha.com
HELIOS-B Shines Bright And Gives Alnylam Pharmaceuticals Another Blockbuster
HELIOS-B Phase III study of Amvuttra in patients with ATTR-CM succeeded across all metrics, showing significant benefits in both the combined study population and monotherapy groups. Amvuttra showed strong efficacy in reducing all-cause mortality and cardiovascular events, with positive results in secondary endpoints and a good safety profile. Results support the use of Amvuttra as monotherapy or in combination with stabilizers in people with ATTR-CM, potentially generating billions in incremental revenue for Alnylam.
HELIOS-B Shines Bright And Gives Alnylam Pharmaceuticals Another Blockbuster
HELIOS-B Phase III study of Amvuttra in patients with ATTR-CM succeeded across all metrics, showing significant benefits in both the combined study population and monotherapy groups. Amvuttra showed strong efficacy in reducing all-cause mortality and cardiovascular events, with positive results in secondary endpoints and a good safety profile. Results support the use of Amvuttra as monotherapy or in combination with stabilizers in people with ATTR-CM, potentially generating billions in incremental revenue for Alnylam.
06/24 11:26 EST - investopedia.com
Alnylam Stock Soars on Strong Results in Heart Drug Study
Shares of Alnylam Pharmaceuticals (ALNY) skyrocketed over 31% in early trading Monday after the biopharma firm announced strong results from a late-stage study of its RNA interference drug for a rare heart condition.
Alnylam Stock Soars on Strong Results in Heart Drug Study
Shares of Alnylam Pharmaceuticals (ALNY) skyrocketed over 31% in early trading Monday after the biopharma firm announced strong results from a late-stage study of its RNA interference drug for a rare heart condition.
06/24 11:03 EST - invezz.com
Alnylam Pharmaceuticals reports promising heart disease trial results
Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) opened more than 30% up on Monday after reporting promising results from a late-stage trial of its heart drug. Shares of the biopharmaceutical company are now trading at a year-to-date high of $220.
Alnylam Pharmaceuticals reports promising heart disease trial results
Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) opened more than 30% up on Monday after reporting promising results from a late-stage trial of its heart drug. Shares of the biopharmaceutical company are now trading at a year-to-date high of $220.
06/24 10:52 EST - forbes.com
Alnylam Pharma Shares Surge 30% After Rare Heart Disease Drug Succeeds
Shares of Alnylam Pharmaceuticals rose by over 32%, the company's largest single-day gain in nearly two years, after announcing its drug vutrisiran helped reduce the number of deaths and cardiovascular events in a study of patients with a rare heart disease.
Alnylam Pharma Shares Surge 30% After Rare Heart Disease Drug Succeeds
Shares of Alnylam Pharmaceuticals rose by over 32%, the company's largest single-day gain in nearly two years, after announcing its drug vutrisiran helped reduce the number of deaths and cardiovascular events in a study of patients with a rare heart disease.
06/24 10:33 EST - investorplace.com
Alnylam (ALNY) Stock Soars 30% on Heart Disease Drug Success
Heart disease drugmaker Alnylam (NASDAQ: ALNY ) stock rose sharply on the success of a Phase 3 study of its heart drug, vutrisiran. The drug is also sold as Amvuttra.
Alnylam (ALNY) Stock Soars 30% on Heart Disease Drug Success
Heart disease drugmaker Alnylam (NASDAQ: ALNY ) stock rose sharply on the success of a Phase 3 study of its heart drug, vutrisiran. The drug is also sold as Amvuttra.
06/24 10:22 EST - youtube.com
Cramer's Stop Trading: Alnylam Pharma
CNBC's Jim Cramer explains why he is keeping an eye on shares of Alnylam Pharma.
Cramer's Stop Trading: Alnylam Pharma
CNBC's Jim Cramer explains why he is keeping an eye on shares of Alnylam Pharma.
06/24 09:49 EST - benzinga.com
Alnylam's Closely Watched Phase 3 Heart Disease Trial Of Vutrisiran Hits Primary Endpoint, Shares Surge
Monday, Alnylam Pharmaceuticals Inc ALNY revealed topline results from its HELIOS-B Phase 3 study of vutrisiran, an investigational RNAi therapeutic in development for ATTR amyloidosis with cardiomyopathy (ATTR-CM).
Alnylam's Closely Watched Phase 3 Heart Disease Trial Of Vutrisiran Hits Primary Endpoint, Shares Surge
Monday, Alnylam Pharmaceuticals Inc ALNY revealed topline results from its HELIOS-B Phase 3 study of vutrisiran, an investigational RNAi therapeutic in development for ATTR amyloidosis with cardiomyopathy (ATTR-CM).
06/24 08:30 EST - barrons.com
Alnylam Stock Soars After Positive Results From Heart Disease Study
The drugmaker says the study met the primary endpoint and demonstrated significant improvements across all secondary endpoints.
Alnylam Stock Soars After Positive Results From Heart Disease Study
The drugmaker says the study met the primary endpoint and demonstrated significant improvements across all secondary endpoints.
06/24 08:09 EST - investors.com
Alnylam Skyrockets After Hitting A 'Best-Case Scenario' For Heart Drug
Alnylam stock catapulted Monday after its experimental heart-disease treatment topped expectations in a highly anticipated study.
Alnylam Skyrockets After Hitting A 'Best-Case Scenario' For Heart Drug
Alnylam stock catapulted Monday after its experimental heart-disease treatment topped expectations in a highly anticipated study.
06/24 07:51 EST - zacks.com
Alnylam (ALNY) Soars 5.3%: Is Further Upside Left in the Stock?
Alnylam (ALNY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Alnylam (ALNY) Soars 5.3%: Is Further Upside Left in the Stock?
Alnylam (ALNY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
06/24 07:08 EST - reuters.com
Alnylam's heart disease drug meets main goal in late-stage study
Alnylam Pharmaceuticals said on Monday that its drug vutrisiran met the main goal in a late-stage study testing it as a treatment for a type of heart disease.
Alnylam's heart disease drug meets main goal in late-stage study
Alnylam Pharmaceuticals said on Monday that its drug vutrisiran met the main goal in a late-stage study testing it as a treatment for a type of heart disease.
06/24 07:00 EST - businesswire.com
Alnylam Reports Positive Topline Results from HELIOS-B Phase 3 Study of Vutrisiran, Achieving Statistical Significance on Primary and All Secondary Endpoints in Both Overall and Monotherapy Populations
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced positive topline results from its HELIOS-B Phase 3 study of vutrisiran, an investigational RNAi therapeutic in development for the treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM). The study met the primary endpoint, demonstrating a statistically significant reduction in the composite of all-cause mortality and recurrent cardiovascular (CV) events du.
Alnylam Reports Positive Topline Results from HELIOS-B Phase 3 Study of Vutrisiran, Achieving Statistical Significance on Primary and All Secondary Endpoints in Both Overall and Monotherapy Populations
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced positive topline results from its HELIOS-B Phase 3 study of vutrisiran, an investigational RNAi therapeutic in development for the treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM). The study met the primary endpoint, demonstrating a statistically significant reduction in the composite of all-cause mortality and recurrent cardiovascular (CV) events du.
06/07 18:26 EST - seekingalpha.com
The 'Undercovered' Dozen From June 1-6
The "Undercovered" Dozen highlights twelve ideas from the previous month on stocks with limited coverage. Biotechs CRISPR Therapeutics, Voyager Therapeutics, and Alnylam Pharmaceuticals are covered along with Enovix, Uranium Royalty, Clover Health, and Haliburton. Many of the ideas included have not been discussed in months on the site. One of the ideas is actually first-ever coverage for this ticker.
The 'Undercovered' Dozen From June 1-6
The "Undercovered" Dozen highlights twelve ideas from the previous month on stocks with limited coverage. Biotechs CRISPR Therapeutics, Voyager Therapeutics, and Alnylam Pharmaceuticals are covered along with Enovix, Uranium Royalty, Clover Health, and Haliburton. Many of the ideas included have not been discussed in months on the site. One of the ideas is actually first-ever coverage for this ticker.
06/05 06:14 EST - investorplace.com
June's Biotech Boom: 3 Stocks to Buy for a Summertime Surge
Wall Street regards the healthcare sector as a constant source of innovation, while biotechnology stands at the pinnacle of groundbreaking medical advancements. The long-term potential of robust biotech stocks to buy remains undeniable for investors.
June's Biotech Boom: 3 Stocks to Buy for a Summertime Surge
Wall Street regards the healthcare sector as a constant source of innovation, while biotechnology stands at the pinnacle of groundbreaking medical advancements. The long-term potential of robust biotech stocks to buy remains undeniable for investors.
06/03 14:32 EST - seekingalpha.com
Upcoming Pivotal HELIOS-B Data Looms Large For Alnylam's Valuation
Alnylam Pharmaceuticals, Inc. is set to release clinical data from its HELIOS-B study in late June/early July, and this will have a significant impact on the company's share price. The success of the study could drive the share price to the high-$200 range, while a failure could lead to a drop towards $100. The key question is whether HELIOS-B shows a meaningful efficacy benefit for Amvuttra versus a high bar established by rival compounds.
Upcoming Pivotal HELIOS-B Data Looms Large For Alnylam's Valuation
Alnylam Pharmaceuticals, Inc. is set to release clinical data from its HELIOS-B study in late June/early July, and this will have a significant impact on the company's share price. The success of the study could drive the share price to the high-$200 range, while a failure could lead to a drop towards $100. The key question is whether HELIOS-B shows a meaningful efficacy benefit for Amvuttra versus a high bar established by rival compounds.
05/03 13:31 EST - zacks.com
Alnylam (ALNY) Q1 Loss Narrower Than Expected, Sales Rise Y/Y
Alnylam (ALNY) reports better-than-expected first-quarter 2024 results as both earnings and revenues beat estimates, primarily driven by strong Amvuttra sales.
Alnylam (ALNY) Q1 Loss Narrower Than Expected, Sales Rise Y/Y
Alnylam (ALNY) reports better-than-expected first-quarter 2024 results as both earnings and revenues beat estimates, primarily driven by strong Amvuttra sales.
05/02 12:15 EST - seekingalpha.com
Alnylam Pharmaceuticals, Inc. (ALNY) Q1 2024 Earnings Call Transcript
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY ) Q1 2024 Earnings Conference Call May 2, 2024 8:30 AM ET Company Participants Christine Lindenboom – Senior Vice President-Investor Relations and Corporate Communications Yvonne Greenstreet – Chief Executive Officer Tolga Tanguler – Chief Commercial Officer Pushkal Garg – Chief Medical Officer Jeff Poulton – Chief Financial Officer Conference Call Participants David Lebowitz – Citi Paul Matteis – Stifel Maury Raycroft – Jefferies Gary Nachman – Raymond James Tazeen Ahmad – BofA Securities Ritu Baral – TD Cowen Jessica Fye – JPMorgan Kostas Biliouris – BMO Capital Markets Ellie Merle – UBS Gena Wang – Barclays Mike Ulz – Morgan Stanley Whitney Ijem – CG Operator Good day and thank you for standing by. Welcome to the Alnylam Pharmaceuticals Quarter One 2024 Conference Call.
Alnylam Pharmaceuticals, Inc. (ALNY) Q1 2024 Earnings Call Transcript
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY ) Q1 2024 Earnings Conference Call May 2, 2024 8:30 AM ET Company Participants Christine Lindenboom – Senior Vice President-Investor Relations and Corporate Communications Yvonne Greenstreet – Chief Executive Officer Tolga Tanguler – Chief Commercial Officer Pushkal Garg – Chief Medical Officer Jeff Poulton – Chief Financial Officer Conference Call Participants David Lebowitz – Citi Paul Matteis – Stifel Maury Raycroft – Jefferies Gary Nachman – Raymond James Tazeen Ahmad – BofA Securities Ritu Baral – TD Cowen Jessica Fye – JPMorgan Kostas Biliouris – BMO Capital Markets Ellie Merle – UBS Gena Wang – Barclays Mike Ulz – Morgan Stanley Whitney Ijem – CG Operator Good day and thank you for standing by. Welcome to the Alnylam Pharmaceuticals Quarter One 2024 Conference Call.